Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activities of Anti-PD-1 Monoclonal Antibody BGB-A317 in Chinese Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activities of Anti-PD-1 Monoclonal Antibody BGB-A317 in Chinese Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 13 Apr 2022 Samples from three pooled phase 1/2 studies (NCT02407990, NCT04068519, NCT04004221) assessing between ICs and the clinical efficacy of tislelizumab (TIS), an anti-programmed cell death protein 1 monoclonal antibody, by examining tumor tissues from various tumor types presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 21 Sep 2021 Results of pooled analysis assessing association between use of use of antibiotics and clinical outcomes of tislelizumab presented at the 46th European Society for Medical Oncology Congress
    • 28 Dec 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top